Answer
Emtricitabine/Rilpivirine/Tenofovir Alafenamide Gilead is not recommended for patients with severe hepatic impairment (Child Pugh Class C) because it has not been studied in this population.
Sources for this answer
- Emtricitabine/Rilpivirine/Tenofovir Alafenamide Gilead 200 mg/25 mg/25 mg film-coated tabletsGilead Sciences Ltd · emc · SmPC §4.2 Posology and method of administration · Version 24Document updated
Sources checked